There is currently no specific training available which relates to this group of patients. The medication used and the monitoring required within this patient group, is no different to those who are being treated for menopause, endometriosis, prostate cancer, precocious puberty, constitutional delay in puberty.
Gender dysphoria is not a highly specialised field that involves dangerous medication requiring comprehensive monitoring. The benefits of having access to care far outweigh the risks associated with the denial of that care, particularly in light of NHS waiting times that are in breach of the NHS constitution.
In balancing the risks of providing essential pharmacy services to this patient cohort, there must also be an analysis of the risk of not providing services. Patients who struggle to get access to medical and pharmaceutical healthcare services often turn to the grey or black market.